Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma

10:57 AM EDT, 07/10/2026 (MT Newswires) -- Sanofi (SAN.PA) said Friday the US Food and Drug Administration approved the subcutaneous formulation of Sarclisa Escena for the treatment of multiple myeloma across all existing indications of the drug's intravenous formulation. The approval follows several trials, including the Iraklia phase 3 noninferiority study, which showed that the subcutaneous version of the French pharmaceutical group's treatment worked as well as intravenous infusion. Sanofi added that Sarclisa Escena, combined with standard-of-care regimens, becomes the first anticancer therapy in the US to be administered through both an on-body injector and manual subcutaneous administration.